Search - tctmd.com

Displaying 221 - 240 of 310

Sort: Relevancy | Date

Cerebral Protection in TAVR: New Insights, New Questions as First Device Seeks FDA Clearance

Shelley Wood

September 22, 2016

News Daily News

Sapien 3 Approved for Use in Intermediate-Risk Patients in Europe

Michael O'Riordan

September 20, 2016

News Daily News

较低风险患者 TAVR 后生存率优于手术组，没有“风险升高”

L.A. McKeown

August 24, 2016

News Daily News

Survival Better, No ‘Risk Creep’ for TAVR vs Surgery in Lower-Risk Patients

L.A. McKeown

August 24, 2016

News Daily News

Mejor Supervivencia y Ausencia de ‘Tendencia de Riesgo’ para TAVR vs Cirugía en Pacientes de Menor Riesgo

L.A. McKeown

August 24, 2016

News Daily News

Medtronic Warns of Vascular Trauma, Some Resulting in Death, With CoreValve’s EnVeo R Delivery Catheter

Michael O'Riordan

August 18, 2016

News Daily News

FDA Approves Sapien XT and Sapien 3 for Intermediate-Risk Patients

Yael L. Maxwell

August 18, 2016

News Daily News

Next-Generation CoreValve Device Receives CE Mark for Use in Intermediate-Risk Patients

Todd Neale

August 01, 2016

News Conference News TVT 2016

Teenage TAVR: Should Practice Forge on While Guidelines Grow Up?

Michael O'Riordan

June 20, 2016

Presentation TVT 2016

Evolution From a TAVR Program to an Aortic Valve Center of Excellence

Presenter: A. Pieter Kappetein

June 18, 2016

News Conference News TVT 2016

Not All Valves With Leaflet Thickening Develop Mobility Problems, Repeat 4D CT Shows in SAVORY

Michael O'Riordan

June 18, 2016

Presentation TVT 2016

TVT 1039: Transcatheter Aortic Valve Replacement With Evolut-R CoreValve to Simultaneously Treat Severe Calcific Aortic Stenosis and a Large Aortic Root Pseudo-aneurysm in a High-risk Patient

Presenter: Nirat Beohar

June 17, 2016

News Conference News TVT 2016

What TAVR Needs Next . . . and What It’s Getting

Shelley Wood

June 17, 2016

News Features

Digesting the Valve Degeneration Data: One Month Later, Reactions From TAVR Experts Range From ‘Disturbed’ to Indifferent

Caitlin E. Cox

June 17, 2016

Presentation TVT 2016

Study Design for the EVOLUT R Low-Risk Trial

Presenter: Jeffrey J. Popma

June 16, 2016

Presentation TVT 2016

The EVOLUT R TAVR System: Design Features, Special Attributes, and Brief Clinical Trial Status

Presenter: James B. Hermiller Jr

June 16, 2016

News Conference News TVT 2016

Minimalist Transfemoral TAVR Reduces Costs Without Adversely Affecting Clinical Outcomes

Michael O'Riordan

June 16, 2016

Presentation SOLACI 2016

Medtronic Evolut R System

Presenter: Eberhard Grube

June 10, 2016

News Daily News

大规模 Meta 分析显示，TAVR 与手术 30 天和 1 年死亡率相当

Michael O'Riordan

June 07, 2016

News Daily News

Según un Gran Meta Análisis Parecida Mortalidad al cabo de 30 Días y 1 Año con TAVR Versus Cirugía

Michael O'Riordan

June 07, 2016

Advertisement

Cerebral Protection in TAVR: New Insights, New Questions as First Device Seeks FDA Clearance

Sapien 3 Approved for Use in Intermediate-Risk Patients in Europe

较低风险患者 TAVR 后生存率优于手术组，没有“风险升高”

Survival Better, No ‘Risk Creep’ for TAVR vs Surgery in Lower-Risk Patients

Mejor Supervivencia y Ausencia de ‘Tendencia de Riesgo’ para TAVR vs Cirugía en Pacientes de Menor Riesgo

Medtronic Warns of Vascular Trauma, Some Resulting in Death, With CoreValve’s EnVeo R Delivery Catheter

FDA Approves Sapien XT and Sapien 3 for Intermediate-Risk Patients

Next-Generation CoreValve Device Receives CE Mark for Use in Intermediate-Risk Patients

Teenage TAVR: Should Practice Forge on While Guidelines Grow Up?

Evolution From a TAVR Program to an Aortic Valve Center of Excellence

Not All Valves With Leaflet Thickening Develop Mobility Problems, Repeat 4D CT Shows in SAVORY

TVT 1039: Transcatheter Aortic Valve Replacement With Evolut-R CoreValve to Simultaneously Treat Severe Calcific Aortic Stenosis and a Large Aortic Root Pseudo-aneurysm in a High-risk Patient

What TAVR Needs Next . . . and What It’s Getting

Digesting the Valve Degeneration Data: One Month Later, Reactions From TAVR Experts Range From ‘Disturbed’ to Indifferent

Study Design for the EVOLUT R Low-Risk Trial

The EVOLUT R TAVR System: Design Features, Special Attributes, and Brief Clinical Trial Status

Minimalist Transfemoral TAVR Reduces Costs Without Adversely Affecting Clinical Outcomes

Medtronic Evolut R System

大规模 Meta 分析显示，TAVR 与手术 30 天和 1 年死亡率相当

Según un Gran Meta Análisis Parecida Mortalidad al cabo de 30 Días y 1 Año con TAVR Versus Cirugía

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content